Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H, Ren B, Liu Y, Jiang B, Guo Y, Wei M, Luo L, Kuang X, Qiu M, Lv L, Xu H, Qi R, Yan H, Xu D, Wang Z, Huo CX, Zhu Y, Zhao Y, Wu Y, Qin Z, Su D, Tang T, Wang F, Sun X, Feng Y, Peng H, Wang X, Gao Y, Liu Y, Gong W, Yu F, Liu X, Wang L, Zhou C. Wang H, et al. Among authors: jiang b. J Med Chem. 2020 Dec 24;63(24):15541-15563. doi: 10.1021/acs.jmedchem.0c01346. Epub 2020 Dec 2. J Med Chem. 2020. PMID: 33264017
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang T, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA. Ladomersky E, et al. Among authors: jiang b. Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. doi: 10.1158/1078-0432.CCR-17-3573. Epub 2018 Mar 2. Clin Cancer Res. 2018. PMID: 29500275 Free PMC article.
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, Wang F, Zhu Y, Zhao Y, Wu Y, Qin Z, Sun X, Ren B, Jiang B, Jin W, Shen Z, Tang Z, Song X, Wang L, Liu X, Zhou C, Jiang B. Xiong Y, et al. Among authors: jiang b. Neoplasia. 2020 Sep;22(9):431-440. doi: 10.1016/j.neo.2020.06.009. Epub 2020 Jul 8. Neoplasia. 2020. PMID: 32652442 Free PMC article.
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X, Xue L, Ding X, Zhang J, Jiang L, Liu S, Hou H, Jiang B, Cheng L, Zhu Q, Zhang L, Zhou X, Ma J, Liu Q, Li Y, Ren Z, Jiang B, Song X, Song J, Jin W, Wei M, Shen Z, Liu X, Wang L, Li K, Zhang T. Chen X, et al. Among authors: jiang b, jiang l. Front Immunol. 2022 Feb 22;13:828319. doi: 10.3389/fimmu.2022.828319. eCollection 2022. Front Immunol. 2022. PMID: 35273608 Free PMC article.
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
Jiang B, Zhang T, Deng M, Jin W, Hong Y, Chen X, Chen X, Wang J, Hou H, Gao Y, Gong W, Wang X, Li H, Zhou X, Feng Y, Zhang B, Jiang B, Lu X, Zhang L, Li Y, Song W, Sun H, Wang Z, Song X, Shen Z, Liu X, Li K, Wang L, Liu Y. Jiang B, et al. Front Med. 2023 Dec;17(6):1170-1185. doi: 10.1007/s11684-023-0996-8. Epub 2023 Sep 25. Front Med. 2023. PMID: 37747585
Prevention of dementia using mobile phone applications (PRODEMOS): a multinational, randomised, controlled effectiveness-implementation trial.
van Charante EPM, Hoevenaar-Blom MP, Song M, Andrieu S, Barnes L, Birck C, Brooks R, Coley N, Eggink E, Georges J, Hafdi M, van Gool WA, Handels R, Hou H, Lyu J, Niu Y, Song L, Wang W, Wang Y, Wimo A, Yu Y, Zhang J, Zhang W, Brayne C, Wang W, Richard E; PRODEMOS study group. van Charante EPM, et al. Lancet Healthy Longev. 2024 May 14:S2666-7568(24)00068-0. doi: 10.1016/S2666-7568(24)00068-0. Online ahead of print. Lancet Healthy Longev. 2024. PMID: 38763155 Free article.
8,373 results